Efficacy and safety of anti-PD1 monotherapy or in combination with ipilimumab after BRAF/MEK inhibitors in patients with BRAF mutant metastatic melanoma

Efficacy and safety of anti-PD1 monotherapy or in combination with ipilimumab after BRAF/MEK inhibitors in patients with BRAF mutant metastatic melanoma

BACKGROUND: Patients with V600BRAF mutant metastatic melanoma have higher rates of progression-free survival (PFS) and overall survival (OS) with first-line anti-PD1 (PD1]+anti-CTLA-4 (IPI) versus PD1. Whether this is also true after BRAF/MEKi therapy is unknown. We aimed to determine the efficacy a...

Full description

Bibliographic Details
Main Authors: Ahmed, T. (Author), Allayous, C. (Author), Ascierto, P.A (Author), Carlino, M. (Author), Dimitriou, F. (Author), Gerard, C. (Author), Johnson, D.B (Author), Lebbe, C. (Author), Lo, S. (Author), Long, G. (Author), Mangana, J. (Author), Menzies, A. (Author), Michielin, O. (Author), Pires da Silva, I. (Author), Trojanello, C. (Author), Zakria, D. (Author), Zimmer, L. (Author)
Format: Article
Language:English
Published: NLM (Medline) 2022
Subjects:
immunotherapy
melanoma
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items